Stocks swiftly recovered from the DeepSeek-driven sell-off early in the week but came under pressure on Friday amid concerns ...

Despite supportive earnings, DeepSeek shocked technology stocks. In the busiest week of the earnings season, tariffs and the ...

Why would Trump be OK with forcing Americans to pay more than the rest of the world for their drugs? The answer is simple: ...

CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli Lilly and Palantir, as well as a key inflation metric from the Labor ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the ...

President Donald Trump’s Medicare agency is seeking to bring more transparency to the US government’s drug price negotiation ...

Europe 'Must Fix' Weaknesses to Compete, EU's Von der Leyen Says EU nations must work together quickly to help the bloc compete against global economic powerhouses like China and the U.S., European ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...